Loading
A phase 3 trial of SHR-A2102, Adebrelimab, Gemcitabine, Carboplatin and Cisplatin in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma is a phase 3 interventional study registered as NCT07393542 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 453 participants planned, started 2026-02-12 and due to reach its primary completion in 2028-01-31. Interventions recorded: SHR-A2102 and Adebrelimab and Gemcitabine and cisplatin / carboplatin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SHR-A2102, Muscle-invasive and advanced bladder cancer, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares SHR-A2102, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Platinum agents and the tag pipeline.
Shares SHR-A2102, Muscle-invasive and advanced bladder cancer, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Platinum agents, Monoclonal antibodies and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/